Brought to you by 
Eli Lilly, Ono develop and market respiratory pharmaceutical
18 Jun 2003
Executive Summary
Eli Lilly signed a letter of intent for an exclusive worldwide license--except in Japan, South Korea, and Taiwan--to Ono Pharmaceutical's (prostaglandins and enzyme inhibitors) Phase II sivelestat for acute lung injury and acute respiratory distress syndrome requiring mechanical ventilation.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Eli Lilly, Ono develop and market respiratory pharmaceutical
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice